Fig. 6

Safety outcomes for first-line and second/further-lines mechanisms (any grade AEs; grade 3–5 AEs; AEs leading to discontinuation; AEs leading to death). Abbreviations: AI, Aromatase inhibitor; AKTi, AKT inhibitor; Anti-VEGF, Anti-vascular endothelial growth factor; CDK4/6i, Cyclin-dependent kinase 4 and 6 inhibitors; EGFRi: Epidermal growth factor receptor inhibitor; HDACi, Histone deacetylase inhibitor; ICI, Immune checkpoint inhibitor; mTORi, Mammalian target of rapamycin inhibitor; Pi, Protease inhibitor; PI3Ki, Phosphatidylinositol 3-kinase inhibitor; SERD, Selective estrogen receptor degrader